<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679705</url>
  </required_header>
  <id_info>
    <org_study_id>2008/110</org_study_id>
    <nct_id>NCT00679705</nct_id>
  </id_info>
  <brief_title>Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself</brief_title>
  <official_title>Pilot Study: A Dose-Response Finding Study of Ritodrine (Pre-Par®) to Find the Highest Well Tolerated Dose in Young, Healthy, Female Volunteers. To Find the Size-Order of the Hemodynamical Effects of Ritodrine (PrePar®) and Atosiban (Tractocile®) to Determine the Relevance of a PK/PD-Modelling in the Final Study. Final Study: Investigating the Influence of Tocolytical Medications: Ritodrine (PrePar®) and Atosiban (Tractocile®) at the Clinical Dose on the Hemodynamics and Arterial Function in Healthy Female Volunteers, Compared to Placebo During Continuous Intravenous Infusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will consist of two parts:

      A pilot study in a three-way cross over trial to determine the highest well tolerated dose of
      Ritodrine (Pre-Par®), the impact of Atosiban (Tractocile®) on the hemodynamics and hence the
      design of the final study.

      The final study is planned as a three-way crossover trial to investigate and compare the
      cardiovascular effects of Ritodrine, Atosiban and placebo to relate those effects to the
      pharmacokinetics of Ritodrine and Atosiban (PK/PD modelling).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamical effects of Ritodrine and Atosiban in comparison of those of placebo.</measure>
    <time_frame>240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of the specific dosing levels of the medications on the level of arterial stiffness</measure>
    <time_frame>240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the specific dosing levels of the medications on the effects of the peripheral pulse wave reflections on the central, systolic blood pressure</measure>
    <time_frame>240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the specific dosing levels of the medications on the distensibility of the blood vessel wall</measure>
    <time_frame>240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the specific dosing levels of the medications on the cardiac output and total peripheral resistance</measure>
    <time_frame>240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the specific dosing levels of the medications on peripheral brachial, systolic and diastolic blood pressure</measure>
    <time_frame>240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ritodrine (Pre-Par)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atosiban (Tractocile)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritodrine</intervention_name>
    <description>Ritodrine (Pre-Par), maximum 400 µg/minute, IV</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>Atosiban (Tractocile), maximum 300 µg/minute, IV</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Glucose 5%, IV</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 40 years old;

          -  In good health, especially no cardiovascular diseases, obstructive lung diseases,
             chronic kidney diseases or diabetes mellitus.

          -  Using a proper anticonception method (orally, subcutaneously);

          -  A negative pregnancy test.

        Exclusion Criteria:

          -  Intolerance of Ritodrine;

          -  On chronic medication, except oral and subcutaneous contraception

          -  History or present presentation of cardiac arrythmias;

          -  Risk of being pregnant or less than 6 months postpartum;

          -  Giving breastfeeding;

          -  Previous uteral surgery;

          -  Using an intra-uteral device (IUD);

          -  A severe addiction: nicotine (&gt; 10 cigarettes/day), alcohol (&gt; 3 units/day), caffeine
             (&gt; 5 units/day) or any extralegally drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Van Bortel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>April 17, 2009</last_update_submitted>
  <last_update_submitted_qc>April 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Luc Van Bortel, MD, PhD</name_title>
    <organization>University Hospital Ghent</organization>
  </responsible_party>
  <keyword>Hemodynamics and arterial function of healthy females</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atosiban</mesh_term>
    <mesh_term>Ritodrine</mesh_term>
    <mesh_term>Vasotocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

